Overview

• Two PNAS studies introduce MIGHT and CoMIGHT, designed for high‑dimensional, small‑sample datasets, with code released at treeple.ai for independent testing.
• Across 1,000 blood samples, aneuploidy features yielded 72% sensitivity at 98% specificity, outperforming other AI approaches in consistency and accuracy.
• A companion study found ccfDNA fragmentation signatures in autoimmune and vascular diseases and associated them with elevated inflammatory biomarkers.
• Incorporating inflammatory‑disease data into MIGHT reduced non‑cancer false positives, though inflammation remains a confounder and clinical validation is still required.
• CoMIGHT’s multi‑signal analysis of 125 early breast, 125 early pancreatic, and 500 control samples indicated potential gains for some early detections, and a related editorial flagged eight barriers to clinical integration.